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April 9, 2013:1549–54hospitalizations by the International Classification of Diseases-
Ninth Revision-Clinical Modification principal discharge codes:
402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91,
404.93, or 428.xx.
Among the 274,515 patients with a principal discharge diag-
nosis of HF in the Perspective database, 251,472 (92%) patients
received loop diuretic therapy during their hospital stay. Of those,
218,787 (87%) received furosemide as their only loop diuretic,
6,776 (3%) only received bumetanide, 972 (0.4%) only received
torsemide, whereas 24,937 (10%) were treated with a combination
of these agents.
Most patients with HF received a loop diuretic. However,
torsemide, a new agent with potentially superior clinical effective-
ness, was rarely used. Given the common usage of loop diuretics in
HF and their potential nonequivalence in HF outcomes and
safety endpoints, perhaps it is time for well-designed random-
ized controlled trials, powered for clinical endpoints such as
mortality, readmission, and quality of life, to determine whether
there are differences in the safety and effectiveness of these
agents both for management of chronic HF and for episodes of
acute decompensation.
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Letters to the Editor
The Fontan Operation Starts
With the Cavopulmonary Shunt
We read with great interest the study by Rogers et al. (1) in which
they report their impressive number of 771 patients who under-
went Fontan palliation at their institution. We compliment the
authors on excellent results. Systematic issues in the study design,
however, compel us to comment on their paper.
The Fontan circulation aims at unloading a functionally single
ventricle from its previously volume-overloaded state, while treat-
h
c
p
p
b
d
p
r
u
t
s
p
w
i
(
u
s
i
m
e
o
i
2
t
m
M
w
C
s
a
1
l
a
r
p
a
s
C
*
J
R
T
*
B
U
H
9
t
E
R
1551JACC Vol. 61, No. 14, 2013 Correspondence
April 9, 2013:1549–54ing cyanosis. Most of the patients in Rogers et al. (1) had
ypoplastic left heart syndrome (HLHS). Therefore, the authors
all the Norwood procedure stage 1, cavopulmonary shunt (CPS)
lacement is stage 2, and the Fontan completion is stage 3
alliation. In this frame of reference, the authors unwittingly may
e extending HLHS terminology to all other single ventricular
iagnoses. These different diagnoses call for various different
rocedures before the Fontan operation either to augment or to
educe the pulmonary circulation, but all resulting in a ventric-
lar volume overload. It is the initiation of the Fontan circula-
ion, which normalizes ventricular preload, that is the crucial
tep in altering fundamentally the circulation and ventricular
reload. In the current era, this initiation is the CPS placement,
hich is for that reason the first stage of Fontan palliation and
s where outcome analyses should start. Fontan completion
inferior caval to pulmonary connection) does not alter ventric-
lar preload.
It used to be customary to institute a Fontan circulation in a
ingle operation, associated with 1 early-stage mortality and no
nterstage mortality. However, in staged procedures, interstage
ortality can be substantial (2). Hence it seems odd, in the Rogers
t al. (1) paper, to combine 21 1-stage Fontan procedures with
nly the second stage of the other patients. Ignoring first-stage and
nterstage mortality in such an analysis conceals the genuine
-stage Fontan mortality rates. The relatively low mortality rate in
he Rogers et al. paper (1) is influenced strongly by ignoring the
ortality associated with CPS placement and the interstage period.
uch more could have been concluded from this dataset if patients
ere entered at the initiation of the Fontan circulation, which is at the
PS placement.
Finally, in response to their excellent early survival after second-
tage Fontan procedure, we are curious how their Fontan patients
re doing currently. Because the Rogers et al. (1) study deals with
8 years of operations, it would have been interesting to see the
ong-term attrition in the Fontan circulation.
In conclusion, reporting only the outcome of the second stage of
2-stage Fontan circulation, as in this paper, sheds no light on the
eal issues at stake, specifically results including the entire Fontan
alliative sequence. Calling CPS placement a second-stage palli-
tion before the real Fontan seems to us an obfuscated paradigm
hift, because the Fontan circulation actually has started with the
PS placement.
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Reply
We thank the correspondents for their interest in our recent paper
concerning post-operative outcomes after the Fontan operation
(1). Our goal in reviewing our experience was to identify risk
factors for morbidity and mortality at the time of Fontan surgery.
Although the creation of a total cavopulmonary connection
(TCPC) was performed as a single procedure for a number of
years, that strategy was abandoned because of substantial morbidity
and mortality with the combined procedure. It is now well
established that creating a total cavopulmonary connection in 2
separate operations results in significantly improved outcomes.
Indeed, in our cohort, more than 97% of subjects had a superior
cavopulmonary connection (SCPC) before Fontan surgery.
With due respect to the correspondents, we posit that although
ventricular unloading of the systemic ventricle does begin after
SCPC, there remain substantial differences between the circulation
after SCPC and the circulation after the Fontan operation. After
SCPC, oxygen saturations remain significantly lower than normal,
which may lead to the formation of systemic to pulmonary collateral
vessels and may mitigate the impact of ventricular unloading. Further,
after SCPC, venous flow from the inferior extremities returns to the
heart in the usual fashion, whereas after the Fontan operation, all
venous return, with the exception of fenestration flow, must traverse
the pulmonary vascular bed. This likely has implications for the
distribution of blood flow and may limit cardiac filling.
In this paper, we focused on early outcomes after the Fontan
operation. An evaluation of outcomes over the course of the entire
single ventricle palliative pathway would have to include the
outcome after SCPC along with the outcome up until SCPC,
which may include a Norwood type reconstruction, a systemic to
pulmonary arterial shunt, a pulmonary arterial band, or close
observation without surgical intervention. We do not believe that
grouping SCPC with the Fontan operation is necessary or appro-
priate when evaluating the post-operative outcome of the Fontan
operation itself. The physiological features after SCPC are differ-
ent from those after the Fontan operation, and we believe that the
factors associated with outcomes for each procedure should be
evaluated separately. Although our data do not describe an overall
morbidity and mortality for the entire course of single ventricle
palliation, they do provide important information regarding patient
and procedural factors associated with short-term morbidity and
mortality after the Fontan operation, information relevant to all
patients being considered for total cavopulmonary connection. With
regard to the long-term outcome after Fontan surgery, we agree that
this is an important issue that warrants attention, but this review was
focused on perioperative and early post-operative outcomes.
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